Laboratorios Farmaceuticos Rovi (FRA:41L) LT-Debt-to-Total-Asset: 0.09 (As of Mar. 2026)


FRA:41L Laboratorios Farmaceuticos Rovi SA FRA:41L
93 GF Score
Price €56.75
GF Value €50.70
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset?

Laboratorios Farmaceuticos Rovi FRA:41L -1.99% 93 LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus rates FRA:41L with a GF Score™ of 93/100 and a GF Value™ of €50.70 (Fairly Valued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Laboratorios Farmaceuticos Rovi's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.09.

Laboratorios Farmaceuticos Rovi's long-term debt to total assets ratio declined from Mar. 2025 (0.11) to Mar. 2026 (0.09). It may suggest that Laboratorios Farmaceuticos Rovi is progressively becoming less dependent on debt to grow their business.

Laboratorios Farmaceuticos Rovi  (FRA:41L) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Related Terms

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.07 0.07 0.11 0.10

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.12 0.11 0.10 0.09
FRA:41L
93GF Score
Laboratorios Farmaceuticos Rovi SA FRA:41L
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi LT-Debt-to-Total-Asset Calculation

Laboratorios Farmaceuticos Rovi's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=93.204/955.691
=0.10

Laboratorios Farmaceuticos Rovi's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=86.668/926.315
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.09 mean?
Laboratorios Farmaceuticos Rovi (FRA:41L) has a LT-Debt-to-Total-Asset of 0.09 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset too high?
Laboratorios Farmaceuticos Rovi's current LT-Debt-to-Total-Asset is 0.09. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's LT-Debt-to-Total-Asset of 0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current LT-Debt-to-Total-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi (FRA:41L) is currently considered Fairly Valued. The stock's GF Value™ is €50.70, compared to a current price of €56.75 — trading 11.9% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.09. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (FRA:41L), the current LT-Debt-to-Total-Asset is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (FRA:41L) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of €56.75 is trading 11.9% above its estimated GF Value™ of €50.70. GuruFocus considers Laboratorios Farmaceuticos Rovi to be Fairly Valued.

Key valuation signals for FRA:41L:

  • LT-Debt-to-Total-Asset: 0.09
  • GF Value™: €50.70 vs. price of €56.75 (11.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the FRA:41L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for FRA:41L

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.75
Price
€50.70
GF Value